A position statement of the Slovenian Society for Reproductive Medicine (SSRM) on menopausal medicine
DOI:
https://doi.org/10.6016/ZdravVestn.3512Keywords:
menopause, estrogens, progestogens, treatment, recommendationsAbstract
Management of women in menopause and beyond has significantly changed in the new millennium. Randomized clinical trials have remarkably affected indications for hormonal treatment (HT), therefore posing a great challenge to the menopausal society. However, the most recent knowledge confirms that the benefits still outweigh the risks when HT is selected and used correctly. Therefore, we prepared the updated position statement on menopausal medicine, which is in line with current international recommendations and adjusted to Slovenian circumstances.
Downloads
References
1. Casper RF. Clinical manifestations and diagnosis of menopause. Amsterdam: Wolterskluwer; 2021 [cited 2021 Mar 20]. Available from: https://www.uptodate.com/contents/clinical-manifestations-and-diagnosis-of-menopause?search=menopausis&source=search_result&selectedTitle=1~150&usage_type=default&display_rank=1.
2. Franić D. Hormonske možnosti zdravljenja v perimenopavzi in kasneje. Zdrav Vestn. 2008;77:III-9-15.
3. Sistat. Milijarda podatkov v podatkovni bazi SiStat. Ljubljana: Statistični urad; 2022 [cited 2022 Nov 18]. Available from: https://pxweb.stat.si/SiStatData/pxweb/sl/Data/-/05C1002S.px.
4. Royal College of Obstetricians and Gynaecologists. Developing a Green-top Guideline. Ljubljana: Statistični urad; 2022 [cited 2022 Nov 18]. Available from: https://www.rcog.org.uk/media/rjtfglv4/rcog-guideline-development-guide.pdf.
5. Popovič B. Pomen in pravni status priporočil in smernic. Zdrav Vestn. 2018;87(7—8):365-77.
DOI: 10.6016/ZdravVestn.2485
6. Geršak K, Šoštarič M, Komadina R, Strle F, Fras Z. Pot sprejemanja strokovnih priporočil in kliničnih smernic. Zdrav Vestn. 2018;87(7—8):307-10.
7. Menopavzna medicina. Med Razgl. 2019;58:3-103.
8. The NAMS 2017 Hormone Therapy Position Statement Advisory PanelThe 2017 hormone therapy position statement of The North American Menopause Society. Menopause. 2017;24(7):728-53.
DOI: 10.1097/GME.0000000000000921
PMID: 28650869
9. Baber RJ, Panay N, Fenton A; IMS Writing Group. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-50.
DOI: 10.3109/13697137.2015.1129166
PMID: 26872610
10. Armeni E, Lambrinoudaki I, Ceausu I, Depypere H, Mueck A, Pérez-López FR, et al. Maintaining postreproductive health: A care pathway from the European Menopause and Andropause Society (EMAS). Maturitas. 2016;89:63-72.
DOI: 10.1016/j.maturitas.2016.04.013
PMID: 27180162
11. L’Hermite M. Bioidentical menopausal hormone therapy: registered hormones (non-oral estradiol ± progesterone) are optimal. Climacteric. 2017;20(4):331-8.
DOI: 10.1080/13697137.2017.1291607
PMID: 28301216
12. Franić D, Verdenik I, Meden-Vrtovec H. Effect of counseling on adherence to perimenopausal hormone therapy in Slovenia. Int J Gynaecol Obstet. 2010;111(3):260-3.
DOI: 10.1016/j.ijgo.2010.07.020
PMID: 20870230
13. Murkes D, Lalitkumar PG, Leifland K, Lundström E, Söderqvist G. Percutaneous estradiol/oral micronized progesterone has less-adverse effects and different gene regulations than oral conjugated equine estrogens/medroxyprogesterone acetate in the breasts of healthy women in vivo. Gynecol Endocrinol. 2012;28(sup2):12-5.
DOI: 10.3109/09513590.2012.706670
PMID: 22834417
14. Murkes D, Conner P, Leifland K, Tani E, Beliard A, Lundström E, et al. Effects of percutaneous estradiol-oral progesterone versus oral conjugated equine estrogens-medroxyprogesterone acetate on breast cell proliferation and bcl-2 protein in healthy women. Fertil Steril. 2011;95(3):1188-91.
DOI: 10.1016/j.fertnstert.2010.09.062
PMID: 21067727
15. Canonico M, Carcaillon L, Plu-Bureau G, Oger E, Singh-Manoux A, Tubert-Bitter P, et al. Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen. Stroke. 2016;47(7):1734-41.
DOI: 10.1161/STROKEAHA.116.013052
PMID: 27256671
16. Mirkin S, Amadio JM, Bernick BA, Pickar JH, Archer DF. 17β-Estradiol and natural progesterone for menopausal hormone therapy: REPLENISH phase 3 study design of a combination capsule and evidence review. Maturitas. 2015;81(1):28-35.
DOI: 10.1016/j.maturitas.2015.02.266
PMID: 25835751
17. Mirkin S. Evidence on the use of progesterone in menopausal hormone therapy. Climacteric. 2018;21(4):346-54.
DOI: 10.1080/13697137.2018.1455657
PMID: 29630427
18. Davis SR, Baber R, Panay N, Bitzer J, Cerdas Perez S, Islam RM, et al. Global consensus position statement on the use of testosterone therapy for women. Climacteric. 2019;22(5):429-34.
DOI: 10.1080/13697137.2019.1637079
PMID: 31474158
19. Franić D, Sever M, Janež A, Franić-Ivanišević M, Jensterle M. Individualization of custom compounded hormone therapy in a patient with chemotherapy induced premature ovarian insufficiency and impaired liver function - case report. Acta Clin Croat. 2019;58(1):167-72.
DOI: 10.20471/acc.2019.58.01.21
PMID: 31363339
20. Nacionalni inštitut za javno zdravje. Centralna baza zdravil. Ljubljana: Ministrstvo za zdravje; 2022 [cited 2022 Nov 18]. Available from: http://www.cbz.si/cbz/bazazdr2.nsf/Search/$searchForm?SearchView.
21. British Menopause society (BMS) and Women’s Health Concern. BMS & WHC’s 2020 recommendations on hormone replacement therapy in menopausal women. Marlow: British menopause Society; 2022 [cited 2022 Nov 18]. Available from: https://thebms.org.uk/publications/consensus-statements/bms-whcs-2020-recommendations-on-hormone-replacement-therapy-in-menopausal-women/.
22. Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409.
DOI: 10.1136/bmj.e6409
PMID: 23048011
23. Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC National Cardiac Societies; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021;42(34):3227-337.
DOI: 10.1093/eurheartj/ehab484
PMID: 34458905
24. Boardman HM, Hartley L, Eisinga A, Main C, Roqué i Figuls M, Bonfill Cosp X, et al. Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev. 2015;2015(3).
DOI: 10.1002/14651858.CD002229.pub4
PMID: 25754617
25. Salpeter SR, Walsh JM, Greyber E, Ormiston TM, Salpeter EE. Mortality associated with hormone replacement therapy in younger and older women: a meta-analysis. J Gen Intern Med. 2004;19(7):791-804.
DOI: 10.1111/j.1525-1497.2004.30281.x
PMID: 15209595
26. Wild RA, Wu C, Curb JD, Martin LW, Phillips L, Stefanick M, et al. Coronary heart disease events in the Women’s Health Initiative hormone trials: effect modification by metabolic syndrome: a nested case-control study within the Women’s Health Initiative randomized clinical trials. Menopause. 2013;20(3):254-60.
DOI: 10.1097/gme.0b013e31826f80e0
PMID: 23435021
27. Paschou SA, Papanas N. Type 2 Diabetes Mellitus and Menopausal Hormone Therapy: an Update. Diabetes Ther. 2019;10(6):2313-20.
DOI: 10.1007/s13300-019-00695-y
PMID: 31549295
28. Sare GM, Gray LJ, Bath PM. Association between hormone replacement therapy and subsequent arterial and venous vascular events: a meta-analysis. Eur Heart J. 2008;29(16):2031-41.
DOI: 10.1093/eurheartj/ehn299
PMID: 18599555
29. Magliano DJ, Rogers SL, Abramson MJ, Tonkin AM. Hormone therapy and cardiovascular disease: a systematic review and meta-analysis. BJOG. 2006;113(1):5-14.
DOI: 10.1111/j.1471-0528.2005.00797.x
PMID: 16398764
30. Arana A, Varas C, González-Pérez A, Gutiérrez L, Bjerrum L, García Rodríguez LA. Hormone therapy and cerebrovascular events: a population-based nested case-control study. Menopause. 2006;13(5):730-6.
DOI: 10.1097/01.gme.0000233494.28335.71
PMID: 16946686
31. Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, et al.; European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016;31(5):926-37.
DOI: 10.1093/humrep/dew027
PMID: 27008889
32. European Society for Human Reproduction and Embryology (ESHRE); POI Guideline Development Group. Management of women with premature ovarian insufficiency. Belgium: ESHRE; 2021 [cited 2022 Nov 18]. Available from: https://www.eshre.eu/-/media/sitecore-files/Guidelines/Guidelines/Manual-for-guideline-development_update2017_final.pdf?la=en&hash=9E2645747F26D0AB37BFE8FE12D6BDECBDE0D65B.
33. European Society for Human Reproduction and Embryology (ESHRE). Manual for ESHRE guideline development. Management of women with premature ovarian insufficiency. Belgium: ESHRE; 2021 [cited 2022 Nov 18]. Available from: https://www.eshre.eu/-/media/sitecore-files/Guidelines/Guidelines/Manual-for-guideline-development_update2017_final.pdf?la=en&hash=9E2645747F26D0AB37BFE8FE12D6BDECBDE0D65B.
34. European Society for Human Reproduction and Embryology (ESHRE). Manual for development of recommandations for good clinical practice. Belgium: ESHRE; 2021 [cited 2022 Nov 18]. Available from: https://www.eshre.eu/-/media/sitecore-files/Guidelines/Manual-for--development-of-recommendations_2017_v4.pdf?la=en&hash=6B0ED23D9182A3141975760164B0FA9E2E15D5AF.
35. European Society for Human Reproduction and Embryology (ESHRE)Manual for development od recommandations for good clinical practice. Belgium: ESHRE; 2021[cited 2022 Nov 18]. Available from: https://www.eshre.eu/-/media/sitecore-files/Guidelines/POI/ESHRE-POI-GUIDELINE_Patient-version_noniatrogenicPOI.pdf?la=en&hash=C654BE0F80C07BE0C0477871DBA62327606CBC48.
36. Beaudart C, Dawson A, Shaw SC, Harvey NC, Kanis JA, Binkley N, et al.; IOF-ESCEO Sarcopenia Working Group. Nutrition and physical activity in the prevention and treatment of sarcopenia: systematic review. Osteoporos Int. 2017;28(6):1817-33.
DOI: 10.1007/s00198-017-3980-9
PMID: 28251287
37. Rizzoli R, Stevenson JC, Bauer JM, van Loon LJ, Walrand S, Kanis JA, et al.; ESCEO Task Force. The role of dietary protein and vitamin D in maintaining musculoskeletal health in postmenopausal women: a consensus statement from the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO). Maturitas. 2014;79(1):122-32.
DOI: 10.1016/j.maturitas.2014.07.005
PMID: 25082206
38. Dent E, Morley JE, Cruz-Jentoft AJ, Arai H, Kritchevsky SB, Guralnik J, et al. International Clinical Practice Guidelines for Sarcopenia (ICFSR): Screening, Diagnosis and Management. J Nutr Health Aging. 2018;22(10):1148-61.
DOI: 10.1007/s12603-018-1139-9
PMID: 30498820
39. Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019;30(1):3-44.
DOI: 10.1007/s00198-018-4704-5
PMID: 30324412
40. Cody JD, Richardson K, Moehrer B, Hextall A, Glazener CM. Oestrogen therapy for urinary incontinence in post-menopausal women. Cochrane Database Syst Rev. 2009(4).
PMID: 19821277
41. Hendrix SL, Cochrane BB, Nygaard IE, Handa VL, Barnabei VM, Iglesia C, et al. Effects of estrogen with and without progestin on urinary incontinence. JAMA. 2005;293(8):935-48.
DOI: 10.1001/jama.293.8.935
PMID: 15728164
42. Steinauer JE, Waetjen LE, Vittinghoff E, Subak LL, Hulley SB, Grady D, et al. Postmenopausal hormone therapy: does it cause incontinence? Obstet Gynecol. 2005;106(5 Pt 1):940-5.
DOI: 10.1097/01.AOG.0000180394.08406.15
PMID: 16260510
43. Rahn DD, Ward RM, Sanses TV, Carberry C, Mamik MM, Meriwether KV, et al.; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen use in postmenopausal women with pelvic floor disorders: systematic review and practice guidelines. Int Urogynecol J. 2015;26(1):3-13.
DOI: 10.1007/s00192-014-2554-z
PMID: 25392183
44. Rahn DD, Carberry C, Sanses TV, Mamik MM, Ward RM, Meriwether KV, et al.; Society of Gynecologic Surgeons Systematic Review Group. Vaginal estrogen for genitourinary syndrome of menopause: a systematic review. Obstet Gynecol. 2014;124(6):1147-56.
DOI: 10.1097/AOG.0000000000000526
PMID: 25415166
45. Simon JA, Davis SR, Althof SE, Chedraui P, Clayton AH, Kingsberg SA, et al. Sexual well-being after menopause: An International Menopause Society White Paper. Climacteric. 2018;21(5):415-27.
DOI: 10.1080/13697137.2018.1482647
PMID: 29987939
46. Wierman ME, Arlt W, Basson R, Davis SR, Miller KK, Murad MH, et al. Androgen therapy in women: a reappraisal: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(10):3489-510.
DOI: 10.1210/jc.2014-2260
PMID: 25279570
47. Wierman ME, Nappi RE, Avis N, Davis SR, Labrie F, Rosner W, et al. Endocrine Aspects of Women’s Sexual Function. In: Montorsi F, editor. Sexual medicine. Sexual Dysfunctions in Men and Women. Paris: Health Publication; 2010. pp. 1123-300.
48. Cucinella L, Tiranini L, Nappi RE. Sexual health and contraception in the menopause journey. Best Pract Res Clin Endocrinol Metab. 2024;38(1):101822.
DOI: 10.1016/j.beem.2023.101822
PMID: 37748960
49. The NAMS 2020 GSM Position Statement Editorial PanelThe 2020 genitourinary syndrome of menopause position statement of The North American Menopause Society. Menopause. 2020;27(9):976-92.
DOI: 10.1097/GME.0000000000001609
PMID: 32852449
50. Ravnik Oblak M. Diagnoza sladkorne bolezni. In: Zaletel J, Ravnik-Oblak M, editor. Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2. Ljubljana: Diabetološko društvo Slovenije; 0216.
51. World Health Organization. Definition and diagnosis of diabetes mellitus and intermediate hyperglycaemia. Geneve: WHO; 2019 [cited 2016 Aug 23]. Available from: http://www.who.int/diabetes/publications/Definitionanddiagnosisofdiabetes_new.pdf.
52. World Health Organization.Definition, diagnosis and classification of diabetes mellitus and its complications : report of a WHO consultation. Part 1, Diagnosis and classification of diabetes mellitus. Geneve: WHO; 2019 [cited 2016 Aug 23]. Available from: https://iris.who.int/handle/10665/66040.
53. Paulweber B, Valensi P, Lindström J, Lalic NM, Greaves CJ, McKee M, et al. A European evidence-based guideline for the prevention of type 2 diabetes. Horm Metab Res. 2010;42(S 01):S3-36.
DOI: 10.1055/s-0029-1240928
PMID: 20391306
54. World Health Organization. Use of Glycated Haemoglobin (HbA1c) in the Diagnosis of Diabetes Mellitus. Geneve: WHO; 2016 [cited 2016 Aug 23]. Available from: http://www.who.int/diabetes/publications/report-hba1c_2011.pdf.
55. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-701.
DOI: 10.2337/dci18-0033
PMID: 30291106
56. Zaletel J, Pongrac Barlovič D. Zdravljenje hiperglikemije z zdravili. Slovenske smernice za klinično obravnavo sladkorne bolezni tipa 2. Ljubljana: Združenje endokrinologov Slovenije; 2016 [cited 2016 Aug 23]. Available from: https://endodiab.si/.
57. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al.; Cholesterol Treatment Trialists’ (CTT) Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005;366(9493):1267-78.
DOI: 10.1016/S0140-6736(05)67394-1
PMID: 16214597
58. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al.; ESC Scientific Document Group. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J. 2020;41(1):111-88.
DOI: 10.1093/eurheartj/ehz455
PMID: 31504418
59. Visseren FL, Mach F, Smulders YM, Carballo D, Koskinas KC, Bäck M, et al.; ESC Scientific Document Group. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). Rev Esp Cardiol (Engl Ed). 2022;75(5):429.
DOI: 10.1016/j.rec.2022.04.003
PMID: 35525570
60. Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, Bhala N, et al.; Cholesterol Treatment Trialists’ (CTT) Collaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670-81.
DOI: 10.1016/S0140-6736(10)61350-5
PMID: 21067804
61. National Collaborating Centre for Women’s and Children’s Health (UK)Menopause: Full Guideline. London: National Institute for Health and Care Excellence; 2015.
62. Shibata H, Kato S, Sekine I, Abe K, Araki N, Iguchi H, et al. Diagnosis and treatment of bone metastasis: comprehensive guideline of the Japanese Society of Medical Oncology, Japanese Orthopedic Association, Japanese Urological Association, and Japanese Society for Radiation Oncology. ESMO Open. 2016;1(2):e000037.
DOI: 10.1136/esmoopen-2016-000037
PMID: 27843593
63. Chuang LT, Temin S, Camacho R, Dueñas-Gonzalez A, Feldman S, Gultekin M, et al. Management and Care of Women With Invasive Cervical Cancer: American Society of Clinical Oncology Resource-Stratified Clinical Practice Guideline. J Glob Oncol. 2016;2(5):311-40.
DOI: 10.1200/JGO.2016.003954
PMID: 28717717
64. de Villiers TJ, Hall JE, Pinkerton JV, Pérez SC, Rees M, Yang C, et al. Revised global consensus statement on menopausal hormone therapy. Maturitas. 2016;91:153-5.
DOI: 10.1016/j.maturitas.2016.06.001
PMID: 27389038
65. Royal College of Obstetricians and Gynaecologists (RCOG) and the British Society of Gynaecological Endoscopy. Management of Endometrial Hyperplasia: Green-top guideline No. 67. London: Royal College of Obstericians and Gynaecologists; 2015 [cited 2016 Aug 23]. Available from: https://www.rcog.org.uk/guidance/browse-all-guidance/green-top-guidelines/management-of-endometrial-hyperplasia-green-top-guideline-no-67/.
66. Sjögren LL, Mørch LS, Løkkegaard E. Hormone replacement therapy and the risk of endometrial cancer: A systematic review. Maturitas. 2016;91:25-35.
DOI: 10.1016/j.maturitas.2016.05.013
PMID: 27451318
67. Edey KA, Rundle S, Hickey M. Hormone replacement therapy for women previously treated for endometrial cancer. Cochrane Database Syst Rev. 2018;5(5).
DOI: 10.1002/14651858.CD008830.pub3
PMID: 29763969
68. Morgan KN, Derby CA, Gleason CE. Cognitive Changes with Reproductive Aging, Perimenopause, and Menopause. Obstet Gynecol Clin North Am. 2018;45(4):751-63.
DOI: 10.1016/j.ogc.2018.07.011
PMID: 30401555
69. Savolainen-Peltonen H, Rahkola-Soisalo P, Hoti F, Vattulainen P, Gissler M, Ylikorkala O, et al. Use of postmenopausal hormone therapy and risk of Alzheimer’s disease in Finland: nationwide case-control study. BMJ. 2019;364:l665.
DOI: 10.1136/bmj.l665
PMID: 30842086
70. Vinogradova Y, Dening T, Hippisley-Cox J, Taylor L, Moore M, Coupland C. Use of menopausal hormone therapy and risk of dementia: nested case-control studies using QResearch and CPRD databases. BMJ. 2021;374(2182):n2182.
DOI: 10.1136/bmj.n2182
PMID: 34588168
71. Mintziori G, Lambrinoudaki I, Goulis DG, Ceausu I, Depypere H, Erel CT, et al. EMAS position statement: non-hormonal management of menopausal vasomotor symptoms. Maturitas. 2015;81(3):410-3.
DOI: 10.1016/j.maturitas.2015.04.009
PMID: 25982505
72. Nonhormonal management of menopause-associated vasomotor symptoms: 2015 position statement of The North American Menopause Society. Menopause. 2015;22(11):1155-72.
DOI: 10.1097/GME.0000000000000546
PMID: 26382310
73. Schmidt M, Arjomand-Wölkart K, Birkhäuser MH, Genazzani AR, Gruber DM, Huber J, et al. Consensus: soy isoflavones as a first-line approach to the treatment of menopausal vasomotor complaints. Gynecol Endocrinol. 2016;32(6):427-30.
DOI: 10.3109/09513590.2016.1152240
PMID: 26943176
74. Goldstein KM, Coeytaux RR, Williams JW, Shepherd-Banigan M, Goode AP, McDuffie JR, et al. Nonpharmacologic Treatments for Menopause-Associated Vasomotor Symptoms. Washington (DC): Department of Veterans Affairs (US); 2016.
75. “The 2023 Nonhormone Therapy Position Statement of The North American Menopause Society” Advisory PanelThe 2023 nonhormone therapy position statement of The North American Menopause Society. Menopause. 2023;30(6):573-90.
DOI: 10.1097/GME.0000000000002200
PMID: 37252752
76. Cramer H, Peng W, Lauche R. Yoga for menopausal symptoms-A systematic review and meta-analysis. Maturitas. 2018;109:13-25.
DOI: 10.1016/j.maturitas.2017.12.005
PMID: 29452777
77. Lederman S, Ottery FD, Cano A, Santoro N, Shapiro M, Stute P, et al. Fezolinetant for treatment of moderate-to-severe vasomotor symptoms associated with menopause (SKYLIGHT 1): a phase 3 randomised controlled study. Lancet. 2023;401(10382):1091-102.
DOI: 10.1016/S0140-6736(23)00085-5
PMID: 36924778
78. Stubbs C, Mattingly L, Crawford SA, Wickersham EA, Brockhaus JL, McCarthy LH. Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women. J Okla State Med Assoc. 2017;110(5):272-4.
PMID: 28649145
79. Pinter B, Trojner Bregar A, Imamović Kumalić S. Slovenske smernice za rabo materničnega vložka. Zdrav Vestn. 2012;81(9):598-601.
80. Faculty of Sexual and Repoductive Healthcare. FSRH Clinical Guideline: Contraception for Women Aged over 40 Years (August 2017, amended July 2023). London: FSRH; 2015 [cited 2016 Aug 23]. Available from: https://www.fsrh.org/documents/fsrh-guidance-contraception-for-women-aged-over-40-years-2017.
81. World Health OrganizationMedical eligibility criteria for contraceptive use. 5th ed. Geneva: World Health Organization; 2015.
82. World Health Organization Department of Reproductive Health and Research (WHO/RHR) and Johns Hopkins Bloomberg School of Public Health/Center for Communication Programs(CCP), Knowledge for Health Project. Family Planning: A Global Handbook for Providers (2018 update). Baltimore, Geneva: CCP and WHO; 2018.
83. Pinter B, Korošec S, Srnovršnik T. Slovenske smernice za rabo progestogenske oralne kontracepcije. Zdrav Vestn. 2012;81(5):355-62.
84. Pinter B, Korošec S, Srnovršnik T, Bizjak Ogrinc U. Smernice za rabo kombinirane hormonske kontracepcije. Zdrav Vestn. 2012;81(4):277-88.
85. Liu K, Case A, Cheung AP, Sierra S, AlAsiri S, Carranza-Mamane B, et al.; REPRODUCTIVE ENDOCRINOLOGY AND INFERTILITY COMMITTEE. Advanced reproductive age and fertility. J Obstet Gynaecol Can. 2011;33(11):1165-75.
DOI: 10.1016/S1701-2163(16)35087-3
PMID: 22082792
86. Seifer DB, Wang SF, Frankfurter D. Cumulative live birth rates with autologous oocytes plateau with fewer number of cycles for each year of age > 42. Reprod Biol Endocrinol. 2023;21(1):94.
DOI: 10.1186/s12958-023-01144-z
PMID: 37872609
87. Reljič M, Lovrec VG. Predictive Factors for Live Birth in Autologous in Vitro Fertilization Cycles in Women Aged 40 Years and Older. Zdrav Varst. 2019;58(4):173-8.
DOI: 10.2478/sjph-2019-0022
PMID: 31636725
88. Abusief ME, Missmer SA, Ginsburg ES, Weeks JC, Partridge AH. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer. 2010;116(4):791-8.
DOI: 10.1002/cncr.24835
PMID: 20052714
89. Partridge A, Gelber S, Gelber RD, Castiglione-Gertsch M, Goldhirsch A, Winer E. Age of menopause among women who remain premenopausal following treatment for early breast cancer: long-term results from International Breast Cancer Study Group Trials V and VI. Eur J Cancer. 2007;43(11):1646-53.
DOI: 10.1016/j.ejca.2007.04.006
PMID: 17512721
90. Peccatori FA, Pup LD, Salvagno F, Guido M, Sarno MA, Revelli A, et al. Fertility Preservation Methods in Breast Cancer. Breast Care (Basel). 2012;7(3):197-202.
DOI: 10.1159/000339671
PMID: 22872792
91. Gerber B, von Minckwitz G, Stehle H, Reimer T, Felberbaum R, Maass N, et al.; German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. J Clin Oncol. 2011;29(17):2334-41.
DOI: 10.1200/JCO.2010.32.5704
PMID: 21537042
92. Munster PN, Moore AP, Ismail-Khan R, Cox CE, Lacevic M, Gross-King M, et al. Randomized trial using gonadotropin-releasing hormone agonist triptorelin for the preservation of ovarian function during (neo)adjuvant chemotherapy for breast cancer. J Clin Oncol. 2012;30(5):533-8.
DOI: 10.1200/JCO.2011.34.6890
PMID: 22231041
93. Del Mastro L, Boni L, Michelotti A, Gamucci T, Olmeo N, Gori S, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. JAMA. 2011;306(3):269-76.
DOI: 10.1001/jama.2011.991
PMID: 21771987
94. Demeestere I, Brice P, Peccatori FA, Kentos A, Gaillard I, Zachee P, et al. Gonadotropin-releasing hormone agonist for the prevention of chemotherapy-induced ovarian failure in patients with lymphoma: 1-year follow-up of a prospective randomized trial. J Clin Oncol. 2013;31(7):903-9.
DOI: 10.1200/JCO.2012.42.8185
PMID: 23129737
95. Donnez J, Silber S, Andersen CY, Demeestere I, Piver P, Meirow D, et al. Children born after autotransplantation of cryopreserved ovarian tissue. a review of 13 live births. Ann Med. 2011;43(6):437-50.
DOI: 10.3109/07853890.2010.546807
PMID: 21226660
Downloads
Published
Issue
Section
License
The Author transfers to the Publisher (Slovenian Medical Association) all economic copyrights following form Article 22 of the Slovene Copyright and Related Rights Act (ZASP), including the right of reproduction, the right of distribution, the rental right, the right of public performance, the right of public transmission, the right of public communication by means of phonograms and videograms, the right of public presentation, the right of broadcasting, the right of rebroadcasting, the right of secondary broadcasting, the right of communication to the public, the right of transformation, the right of audiovisual adaptation and all other rights of the author according to ZASP.
The aforementioned rights are transferred non-exclusively, for an unlimited number of editions, for the term of the statutory
The Author can make use of his work himself or transfer subjective rights to others only after 3 months from date of first publishing in the journal Zdravniški vestnik/Slovenian Medical Journal.
The Publisher (Slovenian Medical Association) has the right to transfer the rights of acquired parties without explicit consent of the Author.
The Author consents that the Article be published under the Creative Commons BY-NC 4.0 (attribution-non-commercial) or comparable licence.
